-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Buchang Pharmaceutical (603858.SH) issued an announcement. Recently, Shandong Danhong Pharmaceutical Co., Ltd. (“Shandong Danhong”), a wholly-owned subsidiary of the company, received a “Notice of Termination of Drug Registration Application” for “Englignet Tablets” issued by the State Drug Administration. Empagliflozin tablets are suitable for the treatment of type 2 diabetes. The withdrawal of the application for marketing licensing of engagliflozin tablets will not have a significant impact on current results.

Zhitongcaijing·12/17/2025 10:09:06
Listen to the news
Zhitong Finance App News, Buchang Pharmaceutical (603858.SH) issued an announcement. Recently, Shandong Danhong Pharmaceutical Co., Ltd. (“Shandong Danhong”), a wholly-owned subsidiary of the company, received a “Notice of Termination of Drug Registration Application” for “Englignet Tablets” issued by the State Drug Administration. Empagliflozin tablets are suitable for the treatment of type 2 diabetes. The withdrawal of the application for marketing licensing of engagliflozin tablets will not have a significant impact on current results.